Journal of Affective Disorders
August 1, 2018
Somaye Arabzadeh, Elham Hakkikazazi, Nazila Shahmansouri et al.
Major depressive disorder (MDD) exerts a high health and financial burden on society. The conventional pharmacotherapies for MDD are partially effective and the response to medication often starts with some delay. There are recent reports of antidepressant effects for oral ketamine. We employed a double-blind controlled trial to examine the time course of the therapeutic effect of ketamine when...
Neuropsychopharmacology
August 2018
Jennifer W. Evans, Níall Lally, Li An et al.
The glutamatergic modulator ketamine has striking and rapid antidepressant effects in major depressive disorder (MDD), but its mechanism of action remains unknown. Proton magnetic resonance spectroscopy (1H-MRS) is the only non-invasive method able to directly measure glutamate levels in vivo; in particular, glutamate and glutamine metabolite concentrations are separable by 1H-MRS at 7T. This...
Journal of Hospice and Palliative Nursing
August 1, 2018
Jinsun Yong, Junyang Park, Juhu Kim et al.
This study was conducted to evaluate the effects of the Holy Name Meditation on cancer patients’ spiritual well-being, anxiety, depression, and pain. Twenty-eight patients were enrolled in the control group, and 18 patients were selected for the experimental group. Only the patients in the experimental group completed 5 weeks of the Holy Name Meditation Program. All participants were surveyed...
Journal of Clinical Psychopharmacology
August 1, 2018
Shaina Archer, Carson Chrenek, Jennifer Swainson
Abstract Background Previous studies have demonstrated ketamine to have a rapid antidepressant effect in some patients with treatment-resistant depression (TRD), but the effect is unfortunately not sustained in the long term. In this study, we report on the clinical use of ongoing maintenance ketamine infusions in a group of patients with TRD, beyond an acute course of 6 to 8 ketamine...
Mindfulness
July 21, 2018
Modi Alsubaie, Chris M Dickens, Barnaby D. Dunn et al.
29 citations
Depression co-occurs in 20 % of people with cardiovascular disorders, can persist for years, and predicts worse physical health outcomes. While psychosocial treatments have been shown to treat acute depression effectively in those with comorbid cardiovascular disorders, to date, there has been no evaluation of approaches aiming to prevent relapse and treat residual depression symptoms in this...
Clinical Psychology & Psychotherapy
July 18, 2018
Carina Remmers, Johannes Zimmermann, Alice E. Buxton et al.
10 citations
BACKGROUND: Mindfulness-based interventions (MBIs) are effective in treating major depression. Because mindfulness involves monitoring and accepting current experiences, it may lead people resolve incongruencies between emotional responses that would otherwise remain unnoticed. Mindfulness may thus foster congruence between implicit and explicit emotions. The current randomized controlled trial...
Journal des adolescens
July 13, 2018
Helena Moreira, Maria C Canavarro
The current study aims to investigate whether mindful parenting and adolescents' dispositional mindfulness differ as a function of maternal anxiety and depressive symptoms and to explore the moderating role of these symptoms on the relationship between mindful parenting and adolescents' dispositional mindfulness. A sample of 685 mother-adolescent dyads was collected in Portuguese public...
Neuroreport
July 4, 2018
Wei Pan, Guang-Fen Zhang, Hui-Hui Li et al.
Depression is present in a large proportion of patients suffering from chronic pain, and yet the underlying mechanisms remain to be elucidated. Neuroligins (NLs), as a family of cell-adhesion proteins, are involved in synaptic formation and have been linked to various neuropsychiatric disorders. Here, we studied the alterations in NL1 and NL2 in the medial prefrontal cortex (mPFC), the anterior...
Early Intervention in Psychiatry
July 3, 2018
Jan Sundquist, Karolina Palmér, Ashfaque A. Memon et al.
Although mindfulness‐based group therapies (MGTs) for depressive, anxiety or stress and adjustment disorders are promising, there is a substantial lack of knowledge regarding the long‐term improvements after such therapies in these common psychiatric disorders.
Molecular Psychiatry
July 2018
Bashkim Kadriu, Philip W Gold, D A Luckenbaugh et al.
Patients with major depressive disorder (MDD) have clinically relevant, significant decreases in bone mineral density (BMD). We sought to determine if predictive markers of bone inflammation-the osteoprotegerin (OPG)-RANK-RANKL system or osteopontin (OPN)-play a role in the bone abnormalities associated with MDD and, if so, whether ketamine treatment corrected the abnormalities. The...